The biotechnology recovery is not a farce. These 3 stocks could lead the next bullish leg
The stock market's attention has been focused almost exclusively on artificial intelligence, semiconductors and a handful of large-cap technology companies.…
The stock market's attention has been focused almost exclusively on artificial intelligence, semiconductors and a handful of large-cap technology companies.…
Every weekday, CNBC's Investment Club with Jim Cramer hosts a livestream “morning meeting” at 10:20 a.m. ET. Here's a recap…
CNBC's Jim Cramer said Monday that investors should not fear the latest market rotation. Instead, he believes he is creating…
modern Expanding the portfolio beyond infectious diseases is giving investors a new reason to own stocks after years of uncertainty…
IQVIA, with its vast trove of health information, is at the center of drug development, providing data, tools and services…
AstraZeneca CEO Pascal Soriot said artificial intelligence is helping drugmakers develop drugs faster and make smarter decisions throughout the research…
The JPMorgan Chase & Co. building before the groundbreaking ceremony, at the company's new headquarters at 270 Park Avenue, in…
Obesity drug giant Eli Lilly reported a monster first quarter on Thursday, strengthening our conviction to hold the stock after…
We've taken a closer look at Cardinal Health's quarterly results and Thursday's post-settlement conference call. Our conclusion: The 4.9% drop…
CNBC's Jim Cramer said Thursday that investors should look beyond the market's hottest trades and start looking for opportunities in…